pI: 5.0748 |
Length (AA): 732 |
MW (Da): 82621 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
70 | 189 | 2fe0 (A) | 9 | 131 | 46.00 | 0 | 1 | 0.760034 | -0.88 |
199 | 530 | 1zcm (A) | 33 | 350 | 30.00 | 0 | 1 | 0.803652 | -0.5 |
205 | 726 | 1df0 (A) | 29 | 572 | 29.00 | 0 | 1 | 0.802915 | 1.03 |
213 | 525 | 2r9f (A) | 47 | 345 | 35.00 | 0 | 1 | 0.758396 | 0.02 |
30 | 99 | 4a2n (B) | 135 | 192 | 38.00 | 0.48 | 0.17 | 0.7776 | 1.1 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_156130)
Species | Accession | Gene Product |
---|---|---|
Trypanosoma brucei gambiense | Tbg972.1.1250 | calpain, putative,cysteine peptidase, Clan CA, family C2, putative |
Trypanosoma brucei | Tb927.1.2120 | Calpain-like protein CALP1.3 |
Trypanosoma congolense | TcIL3000_1_1200 | cysteine peptidase, Clan CA, family C2, putative |
Trypanosoma cruzi | TcCLB.506563.200 | calpain cysteine peptidase, putative |
Trypanosoma cruzi | TcCLB.508999.220 | cysteine peptidase, Clan CA, family C2, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.1.2120 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.1.2120 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.1.2120 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.1.2120 this record | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.3
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Leishmania major | calpain family cysteine protease-like protein | 705 aa | 32.7% | 685 aa | Compounds | References |
Leishmania major | cytoskeleton-associated protein CAP5.5, putative,cysteine peptidase, Clan CA, family C2, putative | 723 aa | 33.5% | 668 aa | Compounds | References |
Leishmania major | small myristoylated protein-1 | 131 aa | 48.6% | 109 aa | Compounds | References |
Leishmania major | calpain-like cysteine peptidase, putative,cysteine peptidase, Clan CA, family C2, putative | 414 aa | 32.0% | 416 aa | Compounds | References |
Leishmania major | calpain-like cysteine peptidase, putative,cysteine peptidase, Clan CA, family C2, putative | 687 aa | 38.7% | 680 aa | Compounds | References |
Leishmania major | small myristoylated protein-3, putative | 115 aa | 39.8% | 108 aa | Compounds | References |
Leishmania major | small myristoylated protein-2 | 136 aa | 41.4% | 111 aa | Compounds | References |
1 literature reference was collected for this gene.